These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 36854856)
21. Effect of miR-21 on Apoptosis in Lung Cancer Cell Through Inhibiting the PI3K/ Akt/NF-κB Signaling Pathway in Vitro and in Vivo. Zhou B; Wang D; Sun G; Mei F; Cui Y; Xu H Cell Physiol Biochem; 2018; 46(3):999-1008. PubMed ID: 29669316 [TBL] [Abstract][Full Text] [Related]
22. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling. Liu X; Sun L; Zhang S; Zhang S; Li W J Cell Physiol; 2020 Nov; 235(11):7747-7756. PubMed ID: 31681988 [TBL] [Abstract][Full Text] [Related]
23. Luteolin inhibits viability, migration, angiogenesis and invasion of non-small cell lung cancer vascular endothelial cells via miR-133a-3p/purine rich element binding protein B-mediated MAPK and PI3K/Akt signaling pathways. Pan J; Cai X; Zheng X; Zhu X; Feng J; Wang X Tissue Cell; 2022 Apr; 75():101740. PubMed ID: 35101688 [TBL] [Abstract][Full Text] [Related]
24. Overexpression of FYN suppresses the epithelial-to-mesenchymal transition through down-regulating PI3K/AKT pathway in lung adenocarcinoma. Xue F; Jia Y; Zhao J Surg Oncol; 2020 Jun; 33():108-117. PubMed ID: 32561075 [TBL] [Abstract][Full Text] [Related]
25. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression. Xia A; Li H; Li R; Lu L; Wu X Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933 [TBL] [Abstract][Full Text] [Related]
26. Apigenin inhibits cell proliferation, migration, and invasion by targeting Akt in the A549 human lung cancer cell line. Zhou Z; Tang M; Liu Y; Zhang Z; Lu R; Lu J Anticancer Drugs; 2017 Apr; 28(4):446-456. PubMed ID: 28125432 [TBL] [Abstract][Full Text] [Related]
27. Curcumin inhibits migration and invasion of non-small cell lung cancer cells through up-regulation of miR-206 and suppression of PI3K/AKT/mTOR signaling pathway. Wang N; Feng T; Liu X; Liu Q Acta Pharm; 2020 Sep; 70(3):399-409. PubMed ID: 32074070 [TBL] [Abstract][Full Text] [Related]
28. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer. Wang J; Wang HY; Shen Y; Liang D; Wang HY; Zhang SQ; Cao YX; Cao L Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062 [TBL] [Abstract][Full Text] [Related]
29. Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer. Liu H; Zhu Y; Niu H; Jie J; Hua S; Bai X; Wang S; Song L Cancer Med; 2023 Oct; 12(19):19777-19793. PubMed ID: 37732632 [TBL] [Abstract][Full Text] [Related]
30. lncRNA HOXB-AS3 exacerbates proliferation, migration, and invasion of lung cancer via activating the PI3K-AKT pathway. Jiang W; Kai J; Li D; Wei Z; Wang Y; Wang W J Cell Physiol; 2020 Oct; 235(10):7194-7203. PubMed ID: 32039488 [TBL] [Abstract][Full Text] [Related]
31. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC). Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT. Zhao YY; Jia J; Zhang JJ; Xun YP; Xie SJ; Liang JF; Guo HG; Zhu JZ; Ma SL; Zhang SR Acta Pharmacol Sin; 2021 Aug; 42(8):1288-1297. PubMed ID: 33159174 [TBL] [Abstract][Full Text] [Related]
33. MicroRNA-629 promotes the tumorigenesis of non-small-cell lung cancer by targeting FOXO1 and activating PI3K/AKT pathway. Zhu L; Chen Y; Liu J; Nie K; Xiao Y; Yu H Cancer Biomark; 2020; 29(3):347-357. PubMed ID: 32716350 [TBL] [Abstract][Full Text] [Related]
34. Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway. Zhao L; Zhang J; Fan Y; Li Y Med Sci Monit; 2019 Oct; 25():7864-7871. PubMed ID: 31631173 [TBL] [Abstract][Full Text] [Related]
35. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling. Tang Y; Xiao G; Chen Y; Deng Y Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897 [TBL] [Abstract][Full Text] [Related]
36. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer. Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253 [TBL] [Abstract][Full Text] [Related]
37. [CK2α Regulates the Metastases and Migration of Lung Adenocarcinoma A549 Cell Line through PI3K/Akt/GSK-3β Signal Pathway]. Wu A; Li M; Mai Z; Li S; Yang Z Zhongguo Fei Ai Za Zhi; 2017 Apr; 20(4):233-238. PubMed ID: 28442011 [TBL] [Abstract][Full Text] [Related]
38. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway. Wang S; Cheng Z; Cui Y; Xu S; Luan Q; Jing S; Du B; Li X; Li Y J Transl Med; 2023 Nov; 21(1):819. PubMed ID: 37974250 [TBL] [Abstract][Full Text] [Related]
39. Cancer/testis antigen LDHC promotes proliferation and metastasis by activating the PI3K/Akt/GSK-3β-signaling pathway and the in lung adenocarcinoma. Chen L; Wu Q; Xu X; Yang C; You J; Chen F; Zeng Y Exp Cell Res; 2021 Jan; 398(2):112414. PubMed ID: 33301764 [TBL] [Abstract][Full Text] [Related]
40. Activation of M3 muscarinic receptor by acetylcholine promotes non-small cell lung cancer cell proliferation and invasion via EGFR/PI3K/AKT pathway. Xu R; Shang C; Zhao J; Han Y; Liu J; Chen K; Shi W Tumour Biol; 2015 Jun; 36(6):4091-100. PubMed ID: 25964092 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]